Industry News
Biotechnology Industry News

After a failed merger that led to…
After a failed merger that led to massive layoffs and a lawsuit, solid tumor biotech Lisata Therapeutics has found a new future through a merger with cardio specialist Marea Therapeutics.
Roche is paying Dualitas…
Roche is paying Dualitas Therapeutics $36.5 million upfront to screen over 300,000 novel bispecific combinations in search of new treatments for immunology and inflammation diseases.
North Immunology has decided its…
North Immunology has decided its path to taking an atopic dermatitis drug into the clinic involves going public via a reverse merger.
SK Biopharmaceuticals has added a…
SK Biopharmaceuticals has added a second preclinical Parkinson’s disease therapy to its pipeline courtesy of a $314.8 million biobucks deal with a fellow South Korean drug developer.
A phase 2b study of Longeveron’s…
A phase 2b study of Longeveron’s stem cell therapy in a pediatric heart disease has missed its primary endpoint, prompting the cash-strapped biotech to “review all options” for the business.
Novartis has extended its losing…
Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial.
Senator Todd Young (R-IN),…
Senator Todd Young (R-IN), chairman of the National Security Commission on Emerging Biotechnology, told Fierce why he's concerned about the growth of China's biopharma industry.
Novo’s race to rejuvenate its…
Novo’s race to rejuvenate its cardiometabolic portfolio has seen the rebranded Danish pharma pen a $1.4 billion biobucks pact with oral macrocycle drug start-up Orbis Medicines.
Novartis is paying Sironax $125…
Novartis is paying Sironax $125 million to take up its option on a brain delivery platform, gaining control of technology for getting large molecules to targets in the central nervous system.
Sling Therapeutics has closed a…
Sling Therapeutics has closed a $123 million series C round to advance its oral therapy for thyroid eye disease through a phase 3 trial and hopefully on to commercialization.
After teasing a new initiative to…
After teasing a new initiative to speed up early-stage clinical trials over the summer, the FDA today opened a pilot program for an expedited investigational new drug (IND) application process that the agency hopes will
Connect Biopharma’s hopes of…
Connect Biopharma’s hopes of dethroning Dupixent took a knock as its IL-4/IL-13 blocker missed the primary endpoint of a phase 2 asthma study.
Eli Lilly’s ongoing attempt to…
Eli Lilly’s ongoing attempt to strengthen its genetic medicine offering has seen the company pledge up to $237 million in biobucks per program as part of a collaboration with QurCan Therapeutics.
Sionna Therapeutics is laying off…
Sionna Therapeutics is laying off almost half its workforce as the company recovers from the failure of its closely watched cystic fibrosis add-on program.
GSK has bet up to $750 million on…
GSK has bet up to $750 million on a Chimagen Biosciences trispecific T-cell engager, positioning the Big Pharma to start phase 1 development of the multiple myeloma drug candidate next year. The deal comes two
Novo’s attempted rebrand got off…
Novo’s attempted rebrand got off to a shaky start this week with the news that the pharma had walked away from a $285 million biobucks pact to develop a monthly weight loss drug after less
A phase 2 trial of Johnson &…
A phase 2 trial of Johnson & Johnson’s JNJ-5120 has missed its primary endpoint, denting the prospects of the Contineum Therapeutics-partnered depression drug candidate.
As the FDA marches toward the…
As the FDA marches toward the likely first approval of a psychedelic medicine, the agency today convened a hearing seeking public input on how these drugs should be used, monitored and continuously studied in the
Eli Lilly has put the kibosh on an…
Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
Axoltis Pharma’s phase 2 trial for…
Axoltis Pharma's phase 2 trial for amyotrophic lateral sclerosis may have missed its primary endpoint, but the French biotech has pointed to secondary endpoints to justify persevering with the synthetic peptide.

